Wenn das Medikament von der FDA abgenommen wird..... gehts ab!
Man sollte diese Aktie immer im Auge behalten... Schönes We!
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT®, as a Functional Excipient, with 5-FU to Treat Cancer Newton, Mass. (April 12, 2007) Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel first-in-class carbohydrate compounds, received comments from the U.S. Food & Drug Administration (FDA) relative to its plans for submitting a New Drug Application (NDA), under Section 505 (b)(2) for DAVANAT®, as a functional excipient, to be co-administered with 5- Fluorouracil (5-FU) to treat cancer patients. “In March, we sent the FDA substantial information on chemistry and completed pre-clinical and |